Education
About Us
Working with TipRanks
Follow Us
Tryptamine Therapeutics Limited (AU:TYP)
ASX:TYP
TYP Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.06
Previous CloseN/A
Volume1.74M
Average Volume (3M)1.45M
Market Cap
AU$46.05M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)3.74M
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Feb 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,438,921,900
10 Day Avg. Volume1,875,883
30 Day Avg. Volume1,445,280
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Tryptamine Therapeutics News
PremiumCompany Announcements
Tryptamine Therapeutics Bolsters Team for Groundbreaking Clinical Trial
PremiumCompany Announcements
Tryptamine Therapeutics Advances Psilocybin Product Development
PremiumCompany Announcements
Tryptamine Therapeutics Announces Cessation of Securities
Options Prices
Currently, No data available
---
Ownership Overview
9.07% Insiders
―
Mutual Funds
0.03% Other Institutional Investors
90.90% Public Companies and
Individual Investors
TYP FAQ
What was Tryptamine Therapeutics Limited’s price range in the past 12 months?
Tryptamine Therapeutics Limited lowest share price was AU$0.02 and its highest was AU$0.06 in the past 12 months.
What is Tryptamine Therapeutics Limited’s market cap?
Tryptamine Therapeutics Limited’s market cap is AU$46.05M.
When is Tryptamine Therapeutics Limited’s upcoming earnings report date?
Tryptamine Therapeutics Limited’s upcoming earnings report date is Feb 20, 2025 which is 149 days ago.
How were Tryptamine Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is Tryptamine Therapeutics Limited overvalued?
According to Wall Street analysts Tryptamine Therapeutics Limited’s price is currently Overvalued.
Does Tryptamine Therapeutics Limited pay dividends?
Tryptamine Therapeutics Limited does not currently pay dividends.
What is Tryptamine Therapeutics Limited’s EPS estimate?
Tryptamine Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tryptamine Therapeutics Limited have?
Tryptamine Therapeutics Limited has 1,438,921,900 shares outstanding.
What happened to Tryptamine Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tryptamine Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:TYP
Tryptamine Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:TYP Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
39.13%
12-Months-Change
Fundamentals
Return on Equity
-399.81%
Trailing 12-Months
Asset Growth
71.78%
Trailing 12-Months
Company Description
Tryptamine Therapeutics Limited
Exopharm Ltd is a biopharmaceutical company operating in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. Its products Plexaris and Exomere are developed using LEAP manufacturing process.
Technical Analysis
Cynata Therapeutics Limited
―
Prescient Therapeutics Limited
―
Starpharma Holdings Limited
―
Avecho Biotechnology Limited
―
Arovella Therapeutics Limited
―